In terms of inflammatory markers, we observed a significant reduction in CRP (8.54 ± 5.87 vs. 11.86 ± 7.92, p < 0.05, p = 0.005) and ESR (15.1 ± 6.11 vs. 21.96 ± 9.19, p < 0.0001) in the JBQG group compared to the MTX group, indicating that the combination of JBQG can significantly control the inflammation level of RA patients. The gene discussed is CRP; the disease is rheumatoid arthritis.